期刊文献+

原发性高血压中醛固酮合成酶与肥胖及内皮功能的研究进展 被引量:2

The Research of Aldosterone Synthase,Obesity and Endothelial Function in Essential Hypertension
暂未订购
导出
摘要 原发性高血压(EH)是最常见的心血管疾病,我国目前已有患病者达2亿以上。其发生可能与遗传、饮食、肥胖等多种因素相关。肾素-血管紧张素-醛固酮系统(RAAS)激活、水钠潴留、内皮功能异常及交感神经系统活性亢进等危险因素,最终导致血压升高。醛固酮合成酶CYP11B2是醛固酮合成最后的关键性酶,CYP11B2基因-344C/T多态性影响醛固酮的表达。研究发现脂肪组织有存在决定醛固酮合成的关键酶——CYP11B2,同时检测到醛固酮的表达。已知一氧化氮合酶(eNOS)基因和CYP11B2在高血压作用机制上有一定的联系,二者在高血压发病机制中都起调节作用。本文综述了在EH中醛固酮合成酶与肥胖及内皮功能相关的研究进展。 Essential hypertension(EH) is the most common cardiovascular disease,the number of the patients has reached more than 200 million in China at present.Its occurrence may be related to genetics,diet,obesity and other factors.There are some risk factors that lead to high blood pressure eventually Including Renin-angiotensin-aldosterone system(RAAS) activation,water and sodium retention,dysfunction of endodermis and hyperactivity of sympathetic nervous system,etc.Aldosterone synthaseCYP11B2 is the final key enzyme of aldosterone synthesis,CYP11B2 gene-344 C/T polymorphism influence the expression of aldosterone.The study finds that fat tissue determines the key enzyme-CYP11B2 of aldosterone synthesis and the expression of aldosterone could be detected from it.It is known that there is some connection between Nitric oxide synthase(eNOS) gene and CYP11B2 in the pathogenesis of hypertension,both of them play a regulatory role in the hypertension pathogenesis.This article summarized the related research progress on aldosterone synthase,obesity and endothelial function in essential hypertension.
作者 陈元 田国平
出处 《实用心脑肺血管病杂志》 2012年第11期1754-1756,共3页 Practical Journal of Cardiac Cerebral Pneumal and Vascular Disease
关键词 高血压 醛固酮合成酶CYP11B2 肾素-血管紧张素-醛固酮系统 肥胖症 Hypertension Aldosterone Synthase CYP11B2 Renin-angiotensin-aldosterone system Obesity
  • 相关文献

参考文献19

  • 1Barbatr A, Russo P, Siani A, et al. Aldosterone synthase gene ( cypl 1B2) C - 344T polymorphism, plasma aldosterone renin activity and blood pressure in a multi - ethnic population [ J ]. J Hypertens, 2004, 22 (10): 1895-1901.
  • 2龚洪涛,马先林,杜凤和.血管紧张素转换酶和醛固酮合成酶基因多态性与原发性高血压病的关系研究[J].中国全科医学,2011,14(23):2609-2611. 被引量:18
  • 3Nieod J, Bruhin D, Auer L, et al. A biallelie gene polymorphism of CYPI 1B predicts inereased aldosterone to renin ratio in selected hyper- tensive patients [J]. J Clin Endocrino Metab, 2003, 88 (6) : 2495 - 2500.
  • 4Barbato A, Russo P, Siani A, et al. Aldosterone synthase gene (CYP11B2) C - 344T polymorphism, plasma aldosterone, rennin activity and blood pressure in a multi -ethnic population[ J]. Hyper- tens, 2004, 22 (10): 1895-1901.
  • 5孙晓健,侯晓菲,刘少荣,刘文波,陶志刚,李建远.醛固酮合成酶基因-344T/C多态性与山东省汉族人原发性高血压相关性[J].中华医学遗传学杂志,2004,21(5):502-504. 被引量:33
  • 6于汇民,钟久昌,禹艳红,林曙光,靳立军,陆立鹤,张斌,张曹进,董太明,乌汉东,王培宁,高向民.醛固酮合酶基因多态性与高血压患者血压及RAAS激素水平的相关性研究[J].中国分子心脏病学杂志,2010,10(4):226-228. 被引量:8
  • 7杜志荣,张琳,张彬,阿木提.司马义,张明涛,孙玉晶,李博,李广平,邱长春.醛固酮合成酶基因多态性与哈萨克族人群高血压的关系[J].医学研究杂志,2011,40(1):46-49. 被引量:8
  • 8Misra A, Khurana L, et al. Obesity and the metabolic syndrome in de- veloping countries [ J ]. J Clin Endocfinol Metab, 2008, 93 (11Suppl1) : S9 -S30.
  • 9Schlaich MP, Grassi G, Lambert GW, et al. European Society of Hy- pertension Working Group on Obesity. Obesity - induced hypertension and target organ damage: current knowledge and future directions [ J]. J Hypertens, 2009, 27 (2): 207-211.
  • 10Elsayed EF, Tighiouart H, Weiner DE, et al. Waist - to - hip ratio and body mass index as risk factors for cardiovas - cular events in CKD [J]. AmJ Kidney Dis, 2008, 52 (1): 49-57.

二级参考文献39

  • 1全国血压抽样调查协作组.中国人群高血压患病率及其变化趋势[J].高血压杂志,1995,3(A01):7-13. 被引量:508
  • 2赵蕾,王坤,郭艳英,敖由特,徐翀,宋涛,格尔莉,沙根得克.耶里节夫,何秉贤.新疆博尔塔拉蒙古自治州蒙、哈、维、汉4民族30岁以上高血压及部分有关危险因素调查[J].高血压杂志,2006,14(3):214-218. 被引量:70
  • 3牛文全,王建炳,李素洁,周文郁,赵景波,邱长春.北方汉族人群醛固酮合成酶基因多态性与高血压的关系[J].中国医学科学院学报,2007,29(3):329-335. 被引量:11
  • 4Tamaki S, Iwai N, Tsujita Y, et al. Genetic polymorphism of CYP11B2 gene and hypertension in Japanese. Hypertension, 1999, 33: 266-270.
  • 5Yu HM, Lin SG, Liu GZ, et al.Associations between CYP11B2 gene polymorphisms and the response to angiotensin-ennverting enzyme inhibitors. Clin Pharmacol Ther, 2006, 79: 581-589.
  • 6Kupari M, Hautanen A, Lankinen L, et al. Associations between human aldosterone synthase (CYP11B2) gene polymorphisms and left ventricular size, mase, and function. Circulation, 1998, 97: 569- 575.
  • 7Connell JM, Davies E. The new biology of aldosterone. J Endocrinol,200S, 186: 1-20.
  • 8White PC, Slutsker L. Haplotype analysis of CYP 11B2. Endocr Res, 1995, 21: 437-442.
  • 9Clyne CD, Zhang Y, Slutsker L, et al. Angiotensin Ⅱ and potassium regulate human CYP11B2 transcription through common cis-elements. Mol Endocrinol, 1997, 11: 638-649.
  • 10Jeunematre x,Soubrier F,Kotelevtsev YV,et al.Molecular basis of human hypertension:role of angiontensinogen.Cell,1992,71(1):169-180.

共引文献56

同被引文献27

  • 1蔡辉.中国汉族人群醛固酮合成酶基因编码区多态性[J].中国老年学杂志,2014,34(7):1829-1833. 被引量:2
  • 2Zhu JR, Sun NL, Yang K, et al. Efficacy and safety of aliskiren, a direct renin inhibitor, compared with ramipril in Asian patients with mild to moderate hypertension [ J ]. Hypertens Res,2012,35 ( 1 ) :28 - 33.
  • 3Morgado MP, Rolo SA, Castelo - Branco M, et al. Efficacy of de eombirtatiort for the treatment of hypertension : A meta - analytical approach [ J ]. Open Cardiovasc Med J,2011,5(1) :6 -14.
  • 4Huang ML, Li X, Meng Y, et al. Upregulation of angiotensin - converting enzyme(ACE) 2 in hepatic fibrosis by ACE inhibitors [ J]. Clin Exp Pharm Phy,2010,37 (1) :el -e6.
  • 5Brown NJ. Contribution of aldosterone to cardiovascular and renal inflammation and fibrosis [ J ]. Nature Review Nephrology, 2013,9 (8) :459 -469.
  • 6Schumacher CD, Steele RE, Brunner HR. Aldosterone synthase inhibition for the treatment of hypertension and the derived mechanistic requirements for a new therapeutic strategy [ J ]. J Hypertens,2013,31 (10) :2085 - 2093.
  • 7Bertagna X, Pivonello R, F|eseriu M, et al. LCI699, a potent 1113 - hydroxylase inhibitor, normalizes urinary cortisol in patients with Cushing's disease: Results from a muhicenter, proof- of- concept study [ J ]. J Clin Endocrinol Metabol, 2014,99 ( 4 ) : 1375 - 1383.
  • 8穆晓攀,王乃栩,和永爱,杜晓明.血管紧张素转换酶抑制剂福辛普利的研究[J].首都医药,2011,18(16):18-20. 被引量:6
  • 9赵春艳,王京晶,刘洋,赵颖辉,戴金梅.心血管疾病新药阿齐沙坦酯的药理与临床评价[J].中国新药杂志,2011,20(19):1831-1834. 被引量:11
  • 10金航军,杨丽丽.福新普利钠联合吲达帕胺治疗高血压病临床观察[J].陕西医学杂志,2011,40(10):1415-1416. 被引量:1

二级引证文献14

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部